CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00043394. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Open Label, Multi-Center, Dose-Escalation Study Of Subcutaneous CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.
Study identification
- NCT ID
- NCT00043394
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Interventions
- 0.04 mg/kg CpG 7909 Drug
- Herceptin® Drug
- 0.08 mg/kg CpG 7909 Drug
- 0.12 mg/kg CpG 7909 Drug
- 0.16 mg/kg CpG 7909 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2002 (Type not available)
- Primary completion
- Oct 2003 (Actual)
- Completion
- Oct 2003 (Actual)
- Last update posted
- Mar 12, 2009
2002 – 2003
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Berkely | California | 94704 | — |
| Pfizer Investigational Site | Orange | California | 92868 | — |
| Pfizer Investigational Site | Palm Springs | California | 92262 | — |
| Pfizer Investigational Site | New Haven | Connecticut | 06510 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20007-2197 | — |
| Pfizer Investigational Site | Plantation | Florida | 33324 | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48109 | — |
| Pfizer Investigational Site | Dearborn | Michigan | 48126-2641 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48202 | — |
| Pfizer Investigational Site | West Bloomfield | Michigan | 48322-3013 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44195 | — |
| Pfizer Investigational Site | Burlington | Vermont | 05401-3456 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00043394, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2009 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00043394 live on ClinicalTrials.gov.